Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Change in Account Payables: 2012-2024

Historic Change in Account Payables for Theravance Biopharma (TBPH) over the last 13 years, with Dec 2024 value amounting to $750,000.

  • Theravance Biopharma's Change in Account Payables rose 344.55% to $538,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $759,000, marking a year-over-year increase of 296.63%. This contributed to the annual value of $750,000 for FY2024, which is 12400.00% up from last year.
  • Theravance Biopharma's Change in Account Payables amounted to $750,000 in FY2024, which was up 12,400.00% from $6,000 recorded in FY2023.
  • In the past 5 years, Theravance Biopharma's Change in Account Payables ranged from a high of $3.7 million in FY2020 and a low of -$3.5 million during FY2021.
  • In the last 3 years, Theravance Biopharma's Change in Account Payables had a median value of $6,000 in 2023 and averaged -$285,333.
  • Its Change in Account Payables has fluctuated over the past 5 years, first slumped by 196.61% in 2021, then soared by 12,400.00% in 2024.
  • Theravance Biopharma's Change in Account Payables (Yearly) stood at $3.7 million in 2020, then slumped by 196.61% to -$3.5 million in 2021, then soared by 54.39% to -$1.6 million in 2022, then spiked by 100.37% to $6,000 in 2023, then skyrocketed by 12,400.00% to $750,000 in 2024.